Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: http://www.sciepub.com/journal/jcrt Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Go
Journal of Cancer Research and Treatment. 2015, 3(3), 34-36
DOI: 10.12691/jcrt-3-3-1
Open AccessEditorial

Histone Deacetylase Inhibitors: A Hope for Cancer Patients

Ahmed M. Kabel1, 2, and Fahad H. Baali1

1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Pub. Date: December 08, 2015

Cite this paper:
Ahmed M. Kabel and Fahad H. Baali. Histone Deacetylase Inhibitors: A Hope for Cancer Patients. Journal of Cancer Research and Treatment. 2015; 3(3):34-36. doi: 10.12691/jcrt-3-3-1

Abstract

Cancer is a disease caused by genetic and genomic alterations such as amplifications, translocations, deletions or point mutations. Also, cancer development is caused by epigenetic changes due to modifications such as post-translational histone acetylations that can alter DNA and chromatin structures without alterations in the DNA sequence. Histones are the primary protein component of chromatin. It plays an important role in the interactions between the nucleosomes and within the nucleosome itself. Histone deacetylase enzyme is found in the nucleus of the different body cells and plays a vital role in remodeling of chromatin structure and controlling gene expression. Also, it was found to play an important role in the development of cancer. Histone deacetylase inhibitors which are used mainly in psychiatry and neurology may represent a new hope for cancer therapy. They act by various mechanisms which may help in prevention and treatment of cancer. Their combination with various lines of cancer therapy may represent a new hope for cancer patients.

Keywords:
histone deacetylase hope cancer patients

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Mwakwari S, Patil V, Guerrant W, Oyelere A (2010). Macrocyclic Histone Deacetylase Inhibitors. Current Topics in Medicinal Chemistry; 10(14): 1423-40.
 
[2]  Patil V, Guerrant W, Chen PC, Gryder B, Benicewicz DB, Khan SI, et al. (2010). Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorganic& Medicinal Chemistry; 18: 415-25.
 
[3]  Thiagalingam SAM, Cheng K-H, Lee HJ,Mineva N, Thiagalingam A, Ponte JF(2003). Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code. Annals of the New York Academy of Sciences; 983: 84-100.
 
[4]  Dokmanovic M, Clarke C, Marks PA (2007). Histone Deacetylase Inhibitors: Overview and Perspectives. Molecular Cancer Research; 5 (10): 981-9.
 
[5]  Chueh AC, Tse JW, Tögel L, Mariadason JM (2015). Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. Antioxid Redox Signal; 23(1):66-84.
 
[6]  Gryder BE, Rood MK, Johnson KA, Patil V, Raftery ED, Yao L-P, et al. (2013). Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity. J Med Chem; 56 (14): 5782-96.
 
[7]  Vigushin D, Coombes R (2004). Targeted Histone Deacetylase Inhibition for Cancer Therapy. Current Cancer Drug Targets; 4 (2): 205-18.
 
[8]  Kabel AM (2014). Effect of Combination between Methotrexate and Histone Deacetylase Inhibitors on Transplantable Tumor Model. Am J Med Studies; 2(1): 12-18.
 
[9]  Yang X-J, SetoE (2007). HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. Oncogene; 26 (37): 5310-8.
 
[10]  Miller TA, Witter DJ, Belvedere S (2003). Histone deacetylase nhibitors. J Med Chem; 46 (24): 5097-116.
 
[11]  Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005). Clinical Development of Histone Deacetylase Inhibitors As Anticancer Agents. Ann Rev Pharmacol Toxicol; 45: 495-528.
 
[12]  Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, et al. (2007). Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer; 121 (5): 1138-48.
 
[13]  Porcu M, Chiarugi A (2005). The emerging therapeutic potential of sirtuin-interacting drugs: From cell death to lifespan extension. Trends in Pharmacological Sciences; 26 (2): 94–103.
 
[14]  Hahnen E, Hauke J, Tränkle C, Eyüpoglu IY, Wirth B, Blümcke I (2008). Histone deacetylase inhibitors: Possible implications for neurodegenerative disorders. Expert Opinion on Investigational Drugs; 17 (2): 169-84.
 
[15]  Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N, Gao J, et al. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature; 459(7243): 55-60.
 
[16]  Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. (2008). Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau. Journal of Neuroscience; 28 (45): 11500-10.
 
[17]  Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, et al. (2008). Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. The FASEB Journal; 22 (10): 3549-60.
 
[18]  Abdel-Rahman MN, Kabel AM (2012). Comparative study between the effect of methotrexate and valproic acid on solid Ehrlich tumour. J Egypt Natl Canc Inst; 24: 161-7.
 
[19]  Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, Naudi A, et al. (2010). Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Human Molecular Genetics; 19 (10): 2005-14.
 
[20]  Mack GS (2010). To selectivity and beyond. Nature Biotechnology; 28 (12): 1259-66.
 
[21]  Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci; 97 (18): 10014-9.
 
[22]  Kouzarides T, Miska A, McCance EA, Reid DJ, Bannister JL, Kouzarides AJ (1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature; 391 (6667): 597-601.
 
[23]  Matsumura T, Suzuki T, Aizawa K, Munemasa Y, Muto S, Horikoshi M, et al. (2004). The deacetylase HDAC1 negatively regulates the cardiovascular transcription factor Krüppel-like factor 5 through direct interaction. J Biol Chem; 280 (13): 12123-9.
 
[24]  Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al. (2005). Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast. Breast Cancer Research and Treatment; 94 (1): 11-6.
 
[25]  Zhu J, Gu J, Ma J, Xu Z, Tao H (2015). Histone deacetylase inhibitors repress chondrosarcoma cell proliferation. JBUON; 20(1): 269-74.
 
[26]  Pang Q, Chee Y, Fullwood M (2015). Vorinostat, an HDAC inhibitor, perturbs chromatin interactions at MYC/PVT1 locus. Front Genet; 6:270.
 
[27]  Pompo GD, Salerno M, Rotili D, Valente S, Zwergel C, Avnet S, et al. (2015). Novel Histone Deacetylase Inhibitors Induce Growth Arrest, Apoptosis, and Differentiation in Sarcoma Cancer Stem Cells. J Med Chem.
 
[28]  Thurn KT, Thomas S, Moore A, Munster PN (2011). Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol; 7(2): 263-83.
 
[29]  Munster PN, Marchion D, Thomas S, et al. (2009). Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer; 101(7): 1044-50.
 
[30]  Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A (2009). Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther; 8(11): 3075-87.
 
[31]  Sarcar B, Kahali S, Chinnaiyan P (2010). Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor Sn38 in glioblastoma cell lines. J Neurooncol; 99(2): 201-7.
 
[32]  Daud AI, Dawson J, Deconti RC, et al. (2009). Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and Phase I/II clinical trial. Clin Cancer Res; 15(7): 2479-87.
 
[33]  Raha P, Thomas S, Thurn KT, Park J, Munster PN (2015). Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Research; 17: 26.
 
[34]  Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005). Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol Cancer Ther; 4(8): 1231-8.
 
[35]  Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009). Radiosensitization by SAHA in experimental colorectal carcinoma models – in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys; 74(2): 546-52.